Literature DB >> 30043920

Late Follow-up of Patients Submitted to Total Cavopulmonary Derivation: Clinical Aspects, Reinterventions, and Complications Interfering in Morbidity and Mortality.

Cristiane Felix Ximenes Pessotti1, Paula Rodrigues Silva Machado Costa1, Natalia de Freitas Jatene Baranauskas1, Thalyta Madeira Correa1, Ieda Biscegli Jatene1.   

Abstract

OBJECTIVE: To identify main complications in outpatient follow-up, as well as factors before or during operation that may interfere in patient's evolution.
METHODS: Retrospective study of patients submitted to total cavopulmonary shunt with extracardiac conduit from 2000 to 2014 at the Hospital do Coração (São Paulo, Brazil) and who underwent clinical follow-up at this institution.
RESULTS: One hundred and fifty surgeries were performed and 59 patients maintained outpatient follow-up. The mean age of these patients at the time of surgery was 4.45 years (median of 45 months) and 70.2% of them were males. Among the patients undergoing outpatient follow-up, postoperative time at evaluation ranged from 10 days to 145 months; 30 (50.8%) patients had single left ventricle and 29 (49.2%) had single right ventricle (48.2% of these presented with hypoplastic left heart syndrome [HLHS]). Patients with single left ventricle had a higher percentage of reintervention-free survival, but without statistically significant difference. 40% of the patients had no complications and 35% of them presented with thrombosis at some point in the follow-up period, with ventricular dysfunction being the second most frequently found complication (15% of cases), mainly among patients with single right ventricle morphology (P=0.04). Between the patients currently under follow-up, 20 (35%) of them had been evaluated by ultrasonography and had some degree of hepatic congestion and/or hepatomegaly. 16.7% of the patients with such alteration had HLHS (P=0.057).
CONCLUSION: Except for the right ventricular morphology, no other factor has been shown to interfere in late evolution after total cavopulmonary shunt.

Entities:  

Mesh:

Year:  2018        PMID: 30043920      PMCID: PMC6089123          DOI: 10.21470/1678-9741-2017-0217

Source DB:  PubMed          Journal:  Braz J Cardiovasc Surg        ISSN: 0102-7638


  12 in total

1.  Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.

Authors:  Deepika Thacker; Akash Patel; Kathryn Dodds; David J Goldberg; Edisio Semeao; Jack Rychik
Journal:  Ann Thorac Surg       Date:  2010-03       Impact factor: 4.330

2.  Hepatocellular carcinoma after the Fontan procedure.

Authors:  Sumeet K Asrani; Carole A Warnes; Patrick S Kamath
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

3.  Surgical repair of tricuspid atresia.

Authors:  F Fontan; E Baudet
Journal:  Thorax       Date:  1971-05       Impact factor: 9.139

4.  Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.

Authors:  Kurt R Schumacher; Michael Cools; Bryan H Goldstein; Viktoriya Ioffe-Dahan; Karen King; Diane Gaffney; Mark W Russell
Journal:  Pediatr Cardiol       Date:  2011-06-10       Impact factor: 1.655

5.  A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.

Authors:  Paul Monagle; Andrew Cochrane; Robin Roberts; Cedric Manlhiot; Robert Weintraub; Barbara Szechtman; Marina Hughes; Maureen Andrew; Brian W McCrindle
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

6.  Results of staged total cavopulmonary connection for functionally univentricular hearts; comparison of intra-atrial lateral tunnel and extracardiac conduit.

Authors:  Daniëlle Robbers-Visser; Martijn Miedema; Aagje Nijveld; Eric Boersma; Ad J J C Bogers; Felix Haas; Willem A Helbing; Livia Kapusta
Journal:  Eur J Cardiothorac Surg       Date:  2009-11-26       Impact factor: 4.191

7.  Use of ACE inhibitors in Fontan: Rational or irrational?

Authors:  Thomas G Wilson; Ajay J Iyengar; David S Winlaw; Robert G Weintraub; Gavin R Wheaton; Thomas L Gentles; Julian Ayer; Leeanne E Grigg; Robert N Justo; Dorothy J Radford; Andrew Bullock; David S Celermajer; Kim Dalziel; Chris Schilling; Yves d'Udekem
Journal:  Int J Cardiol       Date:  2016-02-18       Impact factor: 4.164

8.  40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients.

Authors:  Kavitha N Pundi; Jonathan N Johnson; Joseph A Dearani; Krishna N Pundi; Zhuo Li; Cynthia A Hinck; Sonja H Dahl; Bryan C Cannon; Patrick W O'Leary; David J Driscoll; Frank Cetta
Journal:  J Am Coll Cardiol       Date:  2015-10-13       Impact factor: 24.094

9.  Comparative trial of the use of antiplatelet and oral anticoagulant in thrombosis prophylaxis in patients undergoing total cavopulmonary operation with extracardiac conduit: echocardiographic, tomographic, scintigraphic, clinical and laboratory analysis.

Authors:  Cristiane Felix Ximenes Pessotti; Marcelo Biscegli Jatene; Ieda Biscegli Jatene; Patrícia Marques Oliveira; Fabiana Moreira Passos Succi; Valeria de Melo Moreira; Rafael Willain Lopes; Simone Rolim Fernandes Fontes Pedra
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

10.  Hepatic Fibrosis Is Universal Following Fontan Operation, and Severity is Associated With Time From Surgery: A Liver Biopsy and Hemodynamic Study.

Authors:  David J Goldberg; Lea F Surrey; Andrew C Glatz; Kathryn Dodds; Michael L O'Byrne; Henry C Lin; Mark Fogel; Jonathan J Rome; Elizabeth B Rand; Pierre Russo; Jack Rychik
Journal:  J Am Heart Assoc       Date:  2017-04-26       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.